Morchella Medical develops and licenses the intellectual property, technology and know-how behind optimized, automated dosing: the methods, models and evidence that let companies bring it to patients.
The newest therapies work only as well as the way each dose is optimized and managed over time: the right starting dose, careful titration, keeping each patient within their therapeutic window, side-effect management, long-term optimization, and the safe combination of treatments.
The scale is already clear. More than a billion people live with obesity, and GLP-1 therapy has brought millions into treatment. Yet more than half discontinue within the first year, often driven by side effects and the absence of careful, individualized titration and management around the molecule. As care moves to the patient and increasingly runs through software and AI, it is the pathway around the molecule, not the molecule alone, that decides whether a therapy works, and whether the company delivering it can stand behind how it is done.
Our core GLP-1 patents are granted in the United States and key territories as method-of-treatment claims, structurally akin to pharmaceutical regimen patents and carrying, in the US, the strong presumption of validity that comes with them. The claims extend from optimized dosing to dynamic dosing alongside co-therapies, and to doing this rigorously when software and AI sit in the clinical loop. Together they form a defensible position over how modern therapies are dosed and managed: the layer that is hardest to build, and hardest to design around.
Our patents span therapeutic areas and the clinical-AI safety layer, including:
The estate is underpinned by the technology and know-how that enables our partners: clinically grounded PK/PD and machine-learning dosing models, backed by real clinical data, and working software modules developed and refined over years.
We partner with pharmaceutical and biotech developers, telehealth and direct-to-patient platforms, and clinical-AI providers.
We provide the IP, evidence and know-how to deploy these methods with clinical, commercial and legal confidence, enabling a new standard of care and the commercial models that come with it.